Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Malignant Melanoma

Free Subscription Articles published in Clin Cancer Res Retrieve available abstracts of 83 articles: HTML format Text format

Single Articles

January 2012
1. WOODMAN SE , Lazar AJ, Aldape KD, Davies MA, et al
   New Strategies in Melanoma: Molecular Testing in Advanced Disease.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
2. PRIETO PA , Yang JC, Sherry RM, Hughes MS, et al
   CTLA-4 Blockade with Ipilimumab: Long-Term Follow-up of 177 Patients with Metastatic Melanoma.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
3. BAJOR DL , Vonderheide RH
   Rehabilitation for oncogene addiction in melanoma: role of immunity in cellular sobriety.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. MINOR DR , Kashani-Sabet M, Garrido M, O'Day SJ, et al
   Sunitinib Therapy for Melanoma Patients with KIT Mutations.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. MARGOLIN KA , Moon J, Flaherty LE, Lao CD, et al
   Randomized Phase II Trial of Sorafenib with Temsirolimus or Tipifarnib in Untreated Metastatic Melanoma (SWOG S0438).
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. ASNAGHI L , Ebrahimi KB, Schreck KC, Bar EE, et al
   Notch signaling promotes growth and invasion in uveal melanoma.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
7. DAVIES MA , Fox PS, Papadopoulos NE, Bedikian AY, et al
   Phase I study of the combination of sorafenib and temsirolimus in patients with metastatic melanoma.
   Clin Cancer Res. 2012.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
8. ALCALA AM , Flaherty KT
   BRAF Inhibitors for the Treatment of Metastatic Melanoma: Clinical Trials and Mechanisms of Resistance.
   Clin Cancer Res. 2012;18:33-9.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   December 2011
9. LUCAS KM , Mohana-Kumaran N, Lau DT, Zhang XD, et al
   Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
   Clin Cancer Res. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. WILMOTT JS , Long GV, Howle JR, Haydu LE, et al
    Selective BRAF inhibitors induce marked T cell infiltration into human metastatic melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
11. RIBAS A , Hersey P, Middleton MR, Gogas HJ, et al
    New challenges in endpoints for drug development in advanced melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2011
12. XU X , Chen L, Guerry D, Dawson PR, et al
    Lymphatic Invasion is Independently Prognostic of Metastasis in Primary Cutaneous Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. LUKE JJ , Hodi FS
    Vemurafenib and BRAF Inhibition: A New Class of Treatment for Metastatic Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. KIRKWOOD JM , Bastholt L, Robert C, Sosman JA, et al
    Phase II, Open-Label, Randomized Trial of the MEK 1/2 Inhibitor Selumetinib as Monotherapy versus Temozolomide in Patients with Advanced Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2011
15. LANDREVILLE S , Agapova OA, Matatall KA, Kneass ZT, et al
    Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
16. EIGENTLER TK , Weide B, de Braud F, Spitaleri G, et al
    A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
17. CHEN P , Huang Y, Bong R, Ding Y, et al
    Tumor-associated macrophages promote angiogenesis and melanoma growth via adrenomedullin in both paracrine and autocrine manners.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. FRUEHAUF JP , Lutzky J, McDermott DF, Brown CK, et al
    Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, 3, in Patients with Metastatic Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. KIM KB , Chesney J, Robinson D, Gardner H, et al
    Phase I/II and Pharmacodynamic Study of Dovitinib (TKI258)-an Inhibitor of Fibroblast Growth Factor Receptors and VEGF Receptors-in Patients with Advanced Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. WEISS G , Grosh WW, Chianese-Bullock KA, Zhao Y, et al
    Molecular insights on the peripheral and intra-tumoral effects of systemic high dose rIL-2 (Aldesleukin) administration for the treatment of metastatic melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
21. PARKHURST MR , Riley JP, Dudley ME, Rosenberg SA, et al
    Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression.
    Clin Cancer Res. 2011;17:6287-97.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2011
22. LIPSON EJ , Drake CG
    Ipilimumab: an Anti-CTLA-4 Antibody for Metastatic Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2011
23. TARHINI AA , Frankel P, Margolin KA, Christensen S, et al
    Aflibercept (VEGF Trap) in Inoperable Stage III or Stage IV Melanoma of Cutaneous or Uveal Origin.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
24. LEE HJ , Wall BA, Wangari-Talbot J, Shin SS, et al
    Glutamatergic Pathway Targeting in Melanoma; Single Agent and Combinatorial Therapies.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2011
25. LESTERHUIS WJ , de Vries IJ, Schreibelt G, Lambeck AJ, et al
    Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
26. TJIN EP , Konijnenberg D, Krebbers G, Mallo H, et al
    T cell immune function in tumor, skin and peripheral blood of advanced stage melanoma patients: implications for immunotherapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
27. YAMANAKA K , Nakahara T, Yamauchi T, Kita A, et al
    Antitumor activity of YM155, a selective small-molecule survivin suppressant, alone and in combination with docetaxel in human malignant melanoma models.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. ZHANG S , Cao Z, Tian H, Shen G, et al
    SKLB1002, a novel potent inhibitor of VEGF receptor 2 signaling, inhibits angiogenesis and tumor growth in vivo.
    Clin Cancer Res. 2011;17:4439-50.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2011
29. HESLOP H
    Getting Personal with Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. FLAHERTY KT , Fisher DE
    New strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advances.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
31. OMHOLT K , Grafstrom E, Kanter-Lewensohn L, Hansson J, et al
    KIT Pathway Alterations in Mucosal Melanomas of the Vulva and Other Sites.
    Clin Cancer Res. 2011;17:3933-42.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. HUANG RR , Jalil J, Economou JS, Chmielowski B, et al
    CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans.
    Clin Cancer Res. 2011;17:4101-9.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. DAVIS MB , Vasquez-Dunddel D, Fu J, Albesiano E, et al
    Intratumoral administration of TLR4 agonist absorbed into a cellular vector improves antitumor responses.
    Clin Cancer Res. 2011;17:3984-92.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. JOSEPH RW , Peddareddigari VR, Liu P, Miller P, et al
    Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2011
35. KYTE JA , Gaudernack G, Dueland S, Trachsel S, et al
    Telomerase peptide vaccination combined with temozolomide: A clinical trial in stage IV melanoma patients.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. DINGS RP , Vang KB, Castermans K, Popescu F, et al
    Enhancement of T-cell-mediated antitumor response: angiostatic adjuvant to immunotherapy against cancer.
    Clin Cancer Res. 2011;17:3134-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
37. ILETT EJ , Barcena M, Errington-Mais F, Griffin S, et al
    Internalization of oncolytic reovirus by human dendritic cell carriers protects the virus from neutralization.
    Clin Cancer Res. 2011;17:2767-76.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
38. ROSENBERG SA , Yang JC, Sherry RM, Kammula US, et al
    Durable Complete Responses in Heavily Pretreted Patients with Metastatic Melanoma Using T Cell Transfer Immunotherapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. AGUILERA R , Saffie C, Tittarelli A, Gonzalez FE, et al
    Heat-shock induction of tumor-derived danger signals mediates rapid monocyte differentiation into clinically effective dendritic cells.
    Clin Cancer Res. 2011;17:2474-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. KLUGER HM , Hoyt K, Bacchiocchi A, Mayer T, et al
    Plasma Markers for Identifying Patients with Metastatic Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
41. ROMANO E , Rossi M, Ratzinger G, de Cos MA, et al
    Peptide-loaded Langerhans cells, despite increased IL15 secretion and T-cell activation in vitro, elicit antitumor T-cell responses comparable to peptide-loaded monocyte-derived dendritic cells in vivo.
    Clin Cancer Res. 2011;17:1984-97.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. BLOCK MS , Nevala WK, Leontovich AA, Markovic SN, et al
    Differential response of human and mouse dendritic cells to VEGF determines interspecies discrepancies in tumor-mediated TH1/TH2 polarity shift.
    Clin Cancer Res. 2011;17:1776-83.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
43. WEBER J , Atkins M, Hwu P, Radvanyi L, et al
    White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.
    Clin Cancer Res. 2011;17:1664-73.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
44. VULTUR A , Villanueva J, Herlyn M
    Targeting BRAF in Advanced Melanoma: A First Step toward Manageable Disease.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. RUDMAN SM , Jameson MB, McKeage MJ, Savage P, et al
    A Phase 1 Study of AS1409, a Novel Antibody-Cytokine Fusion Protein, in Patients with Malignant Melanoma or Renal Cell Carcinoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. PATEL M , Smyth EC, Chapman PB, Wolchok JD, et al
    Therapeutic Implications of the Emerging Molecular Biology of Uveal Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
47. RIBAS A , Weber JS, Chmielowski B, Comin-Anduix B, et al
    Intra-Lymph Node Prime-Boost Vaccination Against Melan A and Tyrosinase for the Treatment of Metastatic Melanoma: Results of a Phase 1 Clinical Trial.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
48. QUANDT D , Fiedler E, Boettcher D, Marsch W, et al
    B7-H4 expression in human melanoma: its association with patients' survival and anti tumor immune response.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
49. BAGLEY RG , Ren Y, Weber W, Yao M, et al
    Placental Growth Factor Upregulation Is a Host Response to Antiangiogenic Therapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. MA X , Piao S, Wang DW, McAfee QW, et al
    Measurements of tumor cell autophagy predict invasiveness, resistance to chemotherapy, and survival in melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. KONG Y , Si L, Zhu Y, Xu XG, et al
    Large Scale Analysis of KIT Aberrations in Chinese Patients with Melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. KHAN AJ , Wall BA, Ahlawat S, Green C, et al
    Riluzole Enhances Ionizing Radiation-induced Cytotoxicity in Human Melanoma Cells that Ectopically Express Metabotropic Glutamate Receptor 1 In Vitro and In Vivo.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
53. ARMSTRONG JL , Corazzari M, Martin S, Pagliarini V, et al
    Oncogenic B-RAF signalling in melanoma impairs the therapeutic advantage of autophagy inhibition.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. RESPA A , Bukur J, Ferrone S, Pawelec G, et al
    Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. ASUNDI J , Reed C, Arca J, McCutcheon K, et al
    An antibody-drug conjugate targeting the endothelin B receptor for the treatment of melanoma.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. FREGNI G , Perier A, Pittari G, Jacobelli S, et al
    Unique functional status of Natural Killer cells in metastatic stage IV melanoma patients and its modulation by chemotherapy.
    Clin Cancer Res. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2010
57. DE VRIES IJ , Castelli C, Huygens C, Jacobs JF, et al
    Frequency of circulating Tregs with demethylated FOXP3 intron 1 in melanoma patients receiving tumor vaccines and potentially Treg-depleting agents.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. AZIZ SA , Jilaveanu LB, Zito C, Camp RL, et al
    Vertical targeting of the phosphatidylinositol-3 kinase pathway as a strategy for treating melanoma.
    Clin Cancer Res. 2010;16:6029-39.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. COMIN-ANDUIX B , Chodon T, Sazegar H, Matsunaga D, et al
    The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
    Clin Cancer Res. 2010;16:6040-8.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
60. SARNAIK AA , Yu B, Yu D, Morelli DR, et al
    Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. JIANG CC , Lai F, Thorne RF, Yang F, et al
    MEK-Independent Survival of B-RAFV600E Melanoma Cells Selected for Resistance to Apoptosis Induced by the RAF Inhibitor PLX4720.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
62. DEL VECCHIO M , Mortarini R, Canova S, Di Guardo L, et al
    BEVACIZUMAB PLUS FOTEMUSTINE AS FIRST-LINE TREATMENT IN METASTATIC MELANOMA PATIENTS: CLINICAL ACTIVITY AND MODULATION OF ANGIOGENESIS AND LYMPHANGIOGENESIS FACTORS.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. DAMATO BE , Dopierala JA, Coupland SE
    Genotypic profiling of 452 choroidal melanomas with Multiplex Ligation-Dependent Probe Amplification.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. ELLERHORST JA , Greene VR, Ekmekcioglu S, Warneke CL, et al
    Clinical Correlates of NRAS and BRAF Mutations in Primary Human Melanoma.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
65. SCHMIDT H , Brown J, Mouritzen U, Selby P, et al
    Safety and Clinical Effect of Subcutaneous Human Interleukin-21 in Patients with Metastatic Melanoma or Renal Cell Carcinoma: A Phase I Trial.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
66. JACOBS JF , Punt CJ, Lesterhuis WJ, Sutmuller RP, et al
    Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment, a phase I/II study in metastatic melanoma patients.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
67. HONG JJ , Rosenberg SA, Dudley ME, Yang JC, et al
    Successful Treatment of Melanoma Brain Metastases With Adoptive Cell Therapy.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
68. JEWELL R , Conway C, Mitra A, Randerson-Moor JA, et al
    Patterns of Expression of DNA Repair Genes and Relapse from Melanoma.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
69. GINSBERG BA , Gallardo HF, Rasalan TS, Adamow M, et al
    Immunologic Response to Xenogeneic gp100 DNA in Melanoma Patients: Comparison of Particle-Mediated Epidermal Delivery with Intramuscular Injection.
    Clin Cancer Res. 2010;16:4057-65.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
70. DUDLEY ME , Gross CA, Langhan MM, Garcia MR, et al
    CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
71. VAISHAMPAYAN UN , Burger AM, Sausville EA, Heilbrun LK, et al
    Safety, efficacy, pharmacokinetics, and pharmacodynamics of the combination of sorafenib and tanespimycin.
    Clin Cancer Res. 2010;16:3795-804.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    May 2010
72. LO AS , Ma Q, Liu DL, Junghans RP, et al
    Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors.
    Clin Cancer Res. 2010;16:2769-80.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
73. CARTHON BC , Wolchok JD, Yuan J, Kamat A, et al
    Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.
    Clin Cancer Res. 2010;16:2861-71.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
74. JONSSON GB , Busch C, Knappskog S, Geisler J, et al
    Gene Expression Profiling-Based Identification of Molecular Subtypes in Stage IV Melanomas with Different Clinical Outcome.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2010
75. BESSER MJ , Shapira-Frommer R, Treves AJ, Zippel D, et al
    Clinical Responses in a Phase II Study Using Adoptive Transfer of Short-term Cultured Tumor Infiltration Lymphocytes in Metastatic Melanoma Patients.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
76. KONG LY , Gelbard A, Wei J, Reina-Ortiz C, et al
    Inhibition of p-STAT3 Enhances IFN-{alpha} Efficacy against Metastatic Melanoma in a Murine Model.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
77. KOYANAGI K , O'Day SJ, Boasberg P, Atkins MB, et al
    Serial Monitoring of Circulating Tumor Cells Predicts Outcome of Induction Biochemotherapy plus Maintenance Biotherapy for Metastatic Melanoma.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
78. NEMATI F , Sastre-Garau X, Laurent C, Couturier J, et al
    Establishment and Characterization of a Panel of Human Uveal Melanoma Xenografts Derived from Primary and/or Metastatic Tumors.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2010
79. SIKORA AG , Gelbard A, Davies MA, Sano D, et al
    Targeted Inhibition of Inducible Nitric Oxide Synthase Inhibits Growth of Human Melanoma In vivo and Synergizes with Chemotherapy.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2010
80. SEGURA MF , Belitskaya-Levy I, Rose AE, Zakrzewski J, et al
    Melanoma MicroRNA Signature Predicts Post-Recurrence Survival.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
81. ROFSTAD EK , Ruud EB, Mathiesen B, Galappathi K, et al
    Associations between radiocurability and interstitial fluid pressure in human tumor xenografts without hypoxic tissue.
    Clin Cancer Res. 2010;16:936-45.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
82. SCHAD K , Baumann Conzett K, Zipser MC, Enderlin V, et al
    Mitogen-activated protein/extracellular signal-regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders.
    Clin Cancer Res. 2010;16:1058-64.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
83. KIRKWOOD JM , Lorigan P, Hersey P, Hauschild A, et al
    Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma.
    Clin Cancer Res. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: